Small molecule · Inhibitor of MEK1/2 (MAP2K1/MAP2K2) (MAP2K1) and RAF kinases (RAF1) · developed by Verastem
Avutometinib is an orally bioavailable inhibitor of the RAF and MEK kinases in the RAS/RAF/MEK/ERK (MAPK) pathway. It induces inactive RAF/MEK complexes that block MEK1/2 phosphorylation and ERK signaling in tumor cells with KRAS mutations. It is studied in ovarian, lung, breast, pancreatic, colorectal and uveal melanoma cancers.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 1, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06072781 | Phase 3 | Low Grade Serous Ovarian Cancer | Recruiting | VSTM |
| NCT07747506 | Phase 2 | Low Grade Ovarian Serous Adenocarcinoma | Not yet recruiting | VSTM |
| NCT05669482 | Phase 1/2 | KRAS Activating Mutation | Active not recruiting | VSTM |
| NCT05608252 | Phase 1/2 | Breast Cancer | Recruiting | VSTM |
| NCT05200442 | Phase 1/2 | Colorectal Cancer | Suspended | VSTM |
| NCT05375994 | Phase 1/2 | Non Small Cell Lung Cancer | Completed | VSTM |
| NCT05074810 | Phase 1/2 | Non Small Cell Lung Cancer | Active not recruiting | VSTM |
| NCT04720417 | Phase 2 | Metastatic Uveal Melanoma | Terminated | VSTM |
| NCT04625270 | Phase 2 | Low Grade Ovarian Serous Adenocarcinoma | Active not recruiting | VSTM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerHormone Receptor-positive Breast CancerKRAS Activating MutationLow Grade Ovarian Serous AdenocarcinomaLow Grade Serous Ovarian CancerMalignant Neoplasm of PancreasNeoplasms PancreaticNon Small Cell Lung CancerOvarian CancerPancreas CancerAdvanced CancerAdvanced Colorectal AdenocarcinomaAdvanced Colorectal Carcinoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the VSTM page.
See VSTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VSTM catalysts and pipeline →